BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Neurobiological Technologies, Inc. (NTII) Receives $1.1 Million Royalty Payment Related To Memantine


10/19/2005 5:10:41 PM

RICHMOND, Calif., May 2 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. today announced that it had received a royalty payment of $1,122,895 from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease in the quarter ended March 31, 2005. NTI receives royalty payments, pursuant to its strategic research and marketing cooperation agreement with Merz, on sales of Memantine by Merz and its marketing partners, Forest Laboratories, Inc. and H. Lundbeck A/S.

Paul E. Freiman, president and chief executive officer, said, "This payment represents the first million dollar plus royalty received under the terms of our agreement with Merz. We are, of course, pleased by the receipt of the funds, which reflect the marketing efforts by Forest Laboratories and Lundbeck. These funds will assist us in our efforts to advance the development of Viprinex(TM) and XERECEPT(R) in late-stage clinical trials."

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. The company is focused on therapies for neurological conditions that occur in connection with dementia, Alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks associated with our dependence on Merz and its marketing partners, as well as other risks detailed from time to time in our Securities and Exchange Commission filings. Actual results may differ materially from those projected. These forward- looking statements represent our judgment as of the date of this release. We disclaim, however, any intent or obligation to update these forward-looking statements.

Neurobiological Technologies Inc.

CONTACT: Paul E. Freiman, President & CEO of NeurobiologicalTechnologies, Inc., +1-510-262-1730; or Cheryl Schneider, VP - InvestorRelations of Porter Le Vay & Rose, Inc., +1-212-564-4700



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES